^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + eseba-vec (HB-200) (HPV-16 E6 protein inhibitor, HPV-16 E7 protein inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
921P - HB-200 arenavirus-based immunotherapy plus pembrolizumab as a first-line treatment of patients with recurrent/metastatic HPV16 positive head and neck cancer
Published date:
10/16/2023
Excerpt:
Among 14 evaluable patients (those with ≥ 2 tumor response assessments) receiving HB-200 plus pembrolizumab, the overall response rate was 43% (1 complete, 5 partial, all confirmed) and the disease control rate was 71%....Preliminary data with HB-200 arenavirus-based immunotherapy plus pembrolizumab demonstrate a favorable safety profile and preliminary efficacy when given as a 1L treatment of patients with R/M HPV16+ PD-L1+ HNSCC.
